Rxi Pharmaceuticals Corp (RXII.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2013||Independence Chairman of the Board|
|63||2015||President, Chief Executive Officer, acting Chief Financial Officer, Director|
|2017||Chief Development Officer|
- BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts
- BRIEF-RXI Pharmaceuticals Says Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 1.2 Million Shares Of Co's Common Stock
- BRIEF-RXi Pharmaceuticals Announces Grant Of Patent From USPTO For sd-rxRNAs To Treat Fibrotic Disorders
- BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9
- BRIEF-Lincoln Park Capital Reports 9.99 Pct Passive Stake In Rxi Pharmaceuticals